Actelion’s ambitious independent-minded CEO will drive up takeover price

This post was originally published on this site

ZURICH (Reuters) – Actelion Chief Executive Jean-Paul Clozel’s desire to keep Europe’s biggest biotech company independent after building it from scratch, means Johnson & Johnson will have to pay a steep premium if a takeover is to succeed.